查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029年全球輔助診斷市場規模研究與預測，按技術、按適應症、按終端用戶和區域分析
市場調查報告書
商品編碼
1269698

2022-2029年全球輔助診斷市場規模研究與預測，按技術、按適應症、按終端用戶和區域分析

Global Companion Diagnostics Market Size study & Forecast, by Technology by Indication, By End User and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

2021年，全球輔助診斷市場的價值約為68億美元，預計在2022-2029年的預測期內將以超過11.0%的健康成長率成長。伴隨診斷是一種用於確保使用類似生物產品或藥物的安全和有效的測試。這些測試通常用於診斷癌症。在此，根據確定的生物標誌物推薦適當的藥物。基於特定病人的反應，這些測試提供個性化的治療。由於癌症發病率的上升和不同適應症的新測試的監管批准的增加等因素，輔助診斷市場正在擴大。

根據世界衛生組織（WHO）2022年2月公佈的統計資料，全球每年約有40萬名兒童罹患癌症，全球癌症發病率的上升促進市場成長。另外，根據世界癌症研究基金國際組織公佈的統計資料，2020年，全球有18,094,716萬例癌症確診。國際癌症研究機構估計，到2040年，全世界的癌症負擔將增加到2750萬新病例。由於全球癌症發病率的增加，這些測試的使用量也在增加，這促進了市場的擴張。此外，預計監管部門對這些測試的各種適應症的批准將擴大市場。例如，2022年8月，美國FDA批准賽默飛世爾科技公司的Oncomine Dx目標測試作為輔助診斷（CDx）。該測試可以識別出表現出HER2（ERBB2）活化性突變（SNVs & Exon 20插入）的非小細胞肺癌腫瘤。此外，藥物和診斷技術的共同開發以及政府的有利支援創造有利的市場成長。然而，藥物開發和相關臨床試驗的高成本可能會阻止市場成長。

全球輔助診斷市場研究考慮的主要地區包括亞太地區、北美、歐洲、拉丁美洲和世界其他地區。北美洲在收入方面占主導地位，因為該地區的藥物發現活動不斷增加，疾病的流行率不斷上升，監管部門的批准也不斷增加。而亞太地區在預測期內預計將以最高的年複合成長率成長，原因是疾病流行率上升、藥物開發合作的數量增加、主要參與者的地理擴張以及政府和非營利組織在市場空間的積極參與。

該研究的目的是確定近年來不同領域和國家的市場規模，並對未來幾年的價值進行預測。本報告旨在將研究涉及的國家內的產業的品質和數量方面都涵蓋其中。

本報告還提供了關於關鍵方面的詳細資訊，如驅動因素和挑戰，這將確定市場的未來成長。此外，還涵蓋了微觀市場的潛在機會，供利益相關者投資，以及對競爭格局和主要參與者的技術產品的詳細分析。

目錄

第一章：執行摘要

  • 市場簡介
  • 2019-2029年全球和細分市場的估計和預測
    • 2019-2029年輔助診斷市場，按地區分類
    • 2019-2029年輔助診斷市場，按技術分類
    • 2019-2029年伴侶診斷市場，按適應症分類
    • 2019-2029年伴侶診斷市場，按終端用戶分類
  • 主要趨勢
  • 估算方法
  • 研究假設

第二章：全球伴隨診斷市場的定義和範圍

  • 本研究的目的
  • 市場定義和範圍
    • 研究的範圍
    • 產業演變
  • 研究中考慮的年份
  • 貨幣兌換率

第三章：全球輔助診斷市場動態

  • 伴隨診斷市場的影響分析（2019-2029）。
    • 市場驅動力
      • 癌症發病率的增加
      • 監管部門對不同適應症的新測試的批准不斷增加
    • 市場挑戰
      • 藥物開發和相關臨床試驗的高成本
    • 市場機會
      • 藥物和診斷技術的共同開發
      • 有利的政府支援

第四章：全球輔助診斷市場產業分析

  • 波特的5力模型
    • 供應商的議價能力
    • 買方的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭性的競爭
  • 波特五力模型的未來方法（2019-2029年）
  • PEST分析
    • 政治因素
    • 經濟
    • 社會
    • 技術
  • 最佳投資機會
  • 最佳策略
  • 產業專家展望
  • 分析師建議和結論

第五章：風險評估：COVID-19的影響

  • 評估COVID-19對產業的整體影響
  • COVID-19前和COVID-19後的市場情況

第六章：全球輔助診斷市場，按技術分類

  • 市場簡介
  • 按技術分類的全球輔助診斷市場，表現- 潛力分析
  • 2019-2029年全球伴侶診斷市場按技術的估計和預測
  • 伴隨診斷市場，次級細項分析
    • 免疫組化(IHC)
    • 聚合酶鍊式反應(PCR)
    • 原位雜交(ISH)
    • 即時PCR (RT-PCR)
    • 基因測序
    • 其他技術

第7章：全球輔助診斷市場，按適應症分類

  • 市場簡介
  • 全球輔助診斷市場，按適應症，性能- 潛力分析
  • 2019-2029年全球輔助診斷市場按適應症的估計和預測
  • 伴隨診斷市場，細項分析
    • 肺癌
    • 乳腺癌
    • 結直腸癌
    • 白血病
    • 黑色素瘤
    • 其他適應症

第8章：全球輔助診斷市場，按終端用戶分類

  • 市場簡介
  • 按終端用戶分類的全球輔助診斷市場，表現- 潛力分析
  • 2019-2029年全球輔助診斷市場按終端用戶的估計和預測
  • 伴隨診斷市場，次級細分市場分析
    • 製藥和生物製藥公司
    • 參考實驗室
    • CROs
    • 其他

第九章：全球輔助診斷市場，區域分析

  • 伴隨診斷市場，區域市場簡介
  • 北美洲
    • 美國
      • 技術分類估計和預測，2019-2029年
      • 2019-2029年適應症分類估計和預測
      • 2019-2029年終端用戶細分估計和預測
    • 加拿大
  • 歐洲輔助診斷市場簡介
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 歐洲其他地區
  • 亞太地區輔助診斷市場概況
    • 中國
    • 中國
    • 日本
    • 澳大利亞
    • 韓國
    • 亞太其他地區
  • 拉美配套診斷市場簡介
    • 巴西
    • 墨西哥
    • 拉美其他地區
  • 世界其他地區

第十章：競爭情報

  • 頂級市場戰略
  • 公司簡介
    • Abbott Laboratories
      • 關鍵資訊
      • 概況
      • 財務（取決於資料的可用性）
      • 產品摘要
      • 近期發展情況
    • Agilent Technologies Inc.
    • F.Hoffmann-La Roche Ltd
    • Biomerieux SA
    • Qiagen NV
    • Siemens Healthcare Gmbh
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation (Beckman Coulter Inc.)
    • Almac Group
    • Illumina Inc.

第十一章：研究過程

  • 研究過程
    • 資料探勘
    • 分析
    • 市場評估
    • 驗證
    • 出版
  • 研究屬性
  • 研究假設

Global Companion Diagnostics Market is valued at approximately USD 6.80 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 11.0% over the forecast period 2022-2029. A companion diagnostic is a test used to ensure the usage of a comparable biological product or medication is both safe and effective. These tests are typically used to diagnose cancer. In this, an appropriate medicine is recommended based on the identified biomarker. Based on a particular patient's response, these tests offer personalized treatment. The Companion Diagnostics market is expanding because of factors such as the increasing incidence of Cancer and rising Regulatory Approvals of New Tests for Different Indications.

The rising prevalence of cancer globally is fostering market growth, according to statistics published by the World Health Organization (WHO) in February 2022, approximately 400,000 children develop cancer worldwide every year. Also, according to the statistics published by the World Cancer Research Fund International, in 2020, there were 18,094,716 million cases of cancer diagnosed globally. The International Agency for Research on Cancer estimated increase in the worldwide burden of cancer is to 27.5 million new cases by 2040. The usage of these tests is increasing due to the increased incidence of cancer worldwide, which is boosting the market's expansion. Also, it is anticipated that regulatory approvals of these tests for various indications will expand the market. For instance, in August 2022, the U.S. FDA approved Thermo Fisher Scientific Inc.'s Oncomine Dx Target Test as a companion diagnostic (CDx). This test identifies non-small cell lung cancer tumours that exhibit HER2 (ERBB2) activating mutations (SNVs & Exon 20 Insertion). In addition, the co-development of drug and diagnostic technology and favorable government support is creating lucrative growth in the market. However, the high cost of drug development and associated clinical trials may halt market growth.

The key regions considered for the Global Companion Diagnostics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the rising drug discovery activities, rising prevalence of diseases and rising regulatory approvals in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising disease prevalence, an increase in the number of collaborations for drug development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • F.Hoffmann-La Roche Ltd
  • Biomerieux SA
  • Qiagen NV
  • Siemens Healthcare Gmbh
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation (Beckman Coulter Inc.)
  • Almac Group
  • Illumina Inc.

Recent Developments in the Market:

  • In January 2022, Amoy Diagnostics Co. Ltd., and PREMIA Holdings (HK) Limited introduced the AmoyDx Pan Lung Cancer PCR Panel (the "PLC Panel") in Japan as a reimbursed companion diagnostic for various anti-cancer drugs.
  • In January 2021,In partnership with OmniSeq Corporation, Laboratory Corporation of America Holdings unveiled OmniSeq INSIGHTsm, a complete tissue-based test for genomic and immunological profiling that makes use of next-generation sequencing (NGS) technology. By advancing precision oncology, the test hopes to enhance patient outcomes..

Global Companion Diagnostics Market Report Scope:

  • Historical Data 2019-2020-2021
  • Base Year for Estimation 2021
  • Forecast period 2022-2029
  • Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered Technology, Indication, End User Region
  • Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Technology offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Technology:

  • Immunohistochemistry (IHC)
  • Polymerase Chain Reaction (PCR)
  • In-situ Hybridization (ISH)
  • Real-time PCR (RT-PCR)
  • Gene Sequencing
  • Other Technologies

By Indication:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Melanoma
  • Other Indications

By End User:

  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories
  • CROs
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Companion Diagnostics Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Companion Diagnostics Market, by Technology, 2019-2029 (USD Billion)
    • 1.2.3. Companion Diagnostics Market, by Indication, 2019-2029 (USD Billion)
    • 1.2.4. Companion Diagnostics Market, by End User, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Companion Diagnostics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Companion Diagnostics Market Dynamics

  • 3.1. Companion Diagnostics Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing incidence of Cancer
      • 3.1.1.2. Rising Regulatory Approvals of New Tests for Different Indications
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Drug Development and Associated Clinical Trials
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Co-development of Drug and Diagnostic Technology
      • 3.1.3.2. Favourable government support

Chapter 4. Global Companion Diagnostics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Companion Diagnostics Market, by Technology

  • 6.1. Market Snapshot
  • 6.2. Global Companion Diagnostics Market by Technology, Performance - Potential Analysis
  • 6.3. Global Companion Diagnostics Market Estimates & Forecasts by Technology 2019-2029 (USD Billion)
  • 6.4. Companion Diagnostics Market, Sub Segment Analysis
    • 6.4.1. Immunohistochemistry (IHC)
    • 6.4.2. Polymerase Chain Reaction (PCR)
    • 6.4.3. In-situ Hybridization (ISH)
    • 6.4.4. Real-time PCR (RT-PCR)
    • 6.4.5. Gene Sequencing
    • 6.4.6. Other Technologies

Chapter 7. Global Companion Diagnostics Market, by Indication

  • 7.1. Market Snapshot
  • 7.2. Global Companion Diagnostics Market by Indication, Performance - Potential Analysis
  • 7.3. Global Companion Diagnostics Market Estimates & Forecasts by Indication 2019-2029 (USD Billion)
  • 7.4. Companion Diagnostics Market, Sub Segment Analysis
    • 7.4.1. Lung Cancer
    • 7.4.2. Breast Cancer
    • 7.4.3. Colorectal Cancer
    • 7.4.4. Leukemia
    • 7.4.5. Melanoma
    • 7.4.6. Other Indications

Chapter 8. Global Companion Diagnostics Market, by End User

  • 8.1. Market Snapshot
  • 8.2. Global Companion Diagnostics Market by End User, Performance - Potential Analysis
  • 8.3. Global Companion Diagnostics Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
  • 8.4. Companion Diagnostics Market, Sub Segment Analysis
    • 8.4.1. Pharmaceutical & Biopharmaceutical Companies
    • 8.4.2. Reference Laboratories
    • 8.4.3. CROs
    • 8.4.4. Others

Chapter 9. Global Companion Diagnostics Market, Regional Analysis

  • 9.1. Companion Diagnostics Market, Regional Market Snapshot
  • 9.2. North America Companion Diagnostics Market
    • 9.2.1. U.S. Companion Diagnostics Market
      • 9.2.1.1. Technology breakdown estimates & forecasts, 2019-2029
      • 9.2.1.2. Indication breakdown estimates & forecasts, 2019-2029
      • 9.2.1.3. End User breakdown estimates & forecasts, 2019-2029
    • 9.2.2. Canada Companion Diagnostics Market
  • 9.3. Europe Companion Diagnostics Market Snapshot
    • 9.3.1. U.K. Companion Diagnostics Market
    • 9.3.2. Germany Companion Diagnostics Market
    • 9.3.3. France Companion Diagnostics Market
    • 9.3.4. Spain Companion Diagnostics Market
    • 9.3.5. Italy Companion Diagnostics Market
    • 9.3.6. Rest of Europe Companion Diagnostics Market
  • 9.4. Asia-Pacific Companion Diagnostics Market Snapshot
    • 9.4.1. China Companion Diagnostics Market
    • 9.4.2. India Companion Diagnostics Market
    • 9.4.3. Japan Companion Diagnostics Market
    • 9.4.4. Australia Companion Diagnostics Market
    • 9.4.5. South Korea Companion Diagnostics Market
    • 9.4.6. Rest of Asia Pacific Companion Diagnostics Market
  • 9.5. Latin America Companion Diagnostics Market Snapshot
    • 9.5.1. Brazil Companion Diagnostics Market
    • 9.5.2. Mexico Companion Diagnostics Market
    • 9.5.3. Rest of Latin America Companion Diagnostics Market
  • 9.6. Rest of The World Companion Diagnostics Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Abbott Laboratories
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Agilent Technologies Inc.
    • 10.2.3. F.Hoffmann-La Roche Ltd
    • 10.2.4. Biomerieux SA
    • 10.2.5. Qiagen NV
    • 10.2.6. Siemens Healthcare Gmbh
    • 10.2.7. Thermo Fisher Scientific Inc.
    • 10.2.8. Danaher Corporation (Beckman Coulter Inc.)
    • 10.2.9. Almac Group
    • 10.2.10. Illumina Inc.

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Companion Diagnostics Market, report scope
  • TABLE 2. Global Companion Diagnostics Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Companion Diagnostics Market estimates & forecasts by Technology 2019-2029 (USD Billion)
  • TABLE 4. Global Companion Diagnostics Market estimates & forecasts by Indication 2019-2029 (USD Billion)
  • TABLE 5. Global Companion Diagnostics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Companion Diagnostics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Companion Diagnostics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Companion Diagnostics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Companion Diagnostics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Companion Diagnostics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Companion Diagnostics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Companion Diagnostics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Companion Diagnostics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Companion Diagnostics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Companion Diagnostics Market
  • TABLE 70. List of primary sources, used in the study of global Companion Diagnostics Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Companion Diagnostics Market, research methodology
  • FIG 2. Global Companion Diagnostics Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Companion Diagnostics Market, key trends 2021
  • FIG 5. Global Companion Diagnostics Market, growth prospects 2022-2029
  • FIG 6. Global Companion Diagnostics Market, porters 5 force model
  • FIG 7. Global Companion Diagnostics Market, pest analysis
  • FIG 8. Global Companion Diagnostics Market, value chain analysis
  • FIG 9. Global Companion Diagnostics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Companion Diagnostics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Companion Diagnostics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Companion Diagnostics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Companion Diagnostics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Companion Diagnostics Market, regional snapshot 2019 & 2029
  • FIG 15. North America Companion Diagnostics Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Companion Diagnostics Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Companion Diagnostics Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Companion Diagnostics Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Companion Diagnostics Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable